Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
167,888,095
-
Total 13F shares
-
44,548,308
-
Share change
-
+11,909,644
-
Total reported value
-
$97,118,414
-
Put/Call ratio
-
4.3%
-
Price per share
-
$2.18
-
Number of holders
-
85
-
Value change
-
+$26,024,246
-
Number of buys
-
46
-
Number of sells
-
29
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) as of Q1 2024
As of 31 Mar 2024,
CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,548,308 shares.
The largest 10 holders included
BVF INC/IL, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, ORBIMED ADVISORS LLC, ACADIAN ASSET MANAGEMENT LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Sio Capital Management, LLC, Schonfeld Strategic Advisors LLC, RENAISSANCE TECHNOLOGIES LLC, and BlackRock Inc..
This page lists
85
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.